Adagene, Inc. · NASDAQ:ADAG
Adagene — Investor Presentation (January 2022)
19 slides from Adagene's investor presentation, Jan 12, 2022
Slide 1: Company Overview January 2022
Company Overview January 2022
Slide 2: Disclaimer and Cautionary Note on Forward-Looking Statements
Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . (“ Adagene ” or the “Company”) solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or
Slide 3: Our Goal at Adagene (Ada + Gene)
Our Goal at Adagene (Ada + Gene) We are leveraging our AI - powered Dynamic Precision Library (DPL) to bring highly differentiated antibody - based drugs to cancer patients worldwide 3
Slide 4: Our Story: AI-Powered Adaptation Rooted in Science
Our Story: AI - Powered Adaptation Rooted in Science 4 • Ada Lovelace is the mathematician who invented the first computational algorithm • Gene inherited through millions of years of evolution for survival Ada Gene + to engage dynamically between antibody and antigen to target the conserved epitope
Slide 5: Highlights
Highlights SAFEbody ® ADG126, anti - CD47 (IgG1) in IND - enabling NEO b ody Ρ ADG106, ADG116 Partnerships Leadership POWERb ody Ρ 4 in IND - enabling, including a CD20xCD3 bispecific T - Cell Engager (TCE) and a solid tumor target xCD3 Three - Body Technologies NEObody , SAFEbody , POWERbody AI Pow
Slide 6: Disruptive Technologies For Tailor-Made Antibody Therapeutics
Disruptive Technologies For Tailor - Made Antibody Therapeutics TME Normal Cells Cancer Cells Precision Masking for Antibody Safety Adaptive Binding between CD137 and ADG106 POWERbody 瀧 NEObody 瀧 SAFEbody ® Empowered SAFEbody in different modalities 6
Slide 7: A Robust, Transformative Pipeline of Wholly-Owned Assets
A Robust, Transformative Pipeline of Wholly - Owned Assets* Program & Technology Target Development stage Rights Discovery IND Enabling Ph 1 Ph 2 Pivotal ADG106 NEO CD137 Global ADG116 NEO CTLA - 4 Global ADG126 SAFE CTLA - 4 Global ADG152 POWER CD20xCD3 Global ADG153 SAFE CD47 Global 3 Undisclosed
Slide 8: 2021 Progress
2021 Progress 8 x Advanced two anti - CTLA - 4 programs (ADG116/126) through monotherapy dose escalation and started cohort expansion x Demonstrated early signs of efficacy with anti - CTLA - 4 NEObody Ρ (ADG116) in treatment - resistant tumors x Advanced anti - CD137 (ADG106) program in combination
Slide 9: 2022 Expected Milestones & Outlook
2022 Expected Milestones & Outlook - Demonstrate single - agent activity for anti - CTLA - 4 programs (ADG116/126) - Demonstrate safety and preliminary efficacy for anti - CTLA - 4 programs with anti - PD - 1 therapy - Establish safety profile for novel combination of wholly - owned anti - CTLA - 4
Slide 10: Three Wholly-Owned, Tailor-Made Antibodies in Clinic
Three Wholly - Owned, Tailor - Made Antibodies in Clinic NEObody Ρ • Unique epitope triggers a softer ligand blocking and stronger regulatory T - cell depletion • ~25 patients in Ph1 dose escalation; dosing at 10 mg/kg complete • Cohort expansion increased to 10 mg/kg • Ph1b/2 combos with toripalima
Slide 11: ADG106: Anti-CD137 NEObody Program
ADG106: Anti - CD137 NEObody Program Anti - CD137 mAb A ADG106 (Adagene) x Well - tolerated with cohort expansion at 3 & 5mg/kg and at 300mg and 400mg flat doses in US and China x Single agent clinical efficacy with 56% disease control rate (45 of 81 patients evaluated), including PR for a solid tum
Slide 12: ADG116: Anti-CTLA-4 NEObody Program
ADG116: Anti - CTLA - 4 NEObody Program Targeting a unique epitope of CTLA - 4 to overcome longstanding toxicity challenges Ipilimumab ADG116 against neo - epitope of CTLA - 4 x ADG116 t argets a unique epitope with broad species cross - reactivity x Novel MOA: x Potent Treg depletion via strong ADC
Slide 13: ADG126: SAFEbody Anti-CTLA-4 Program
ADG126: SAFEbody Anti - CTLA - 4 Program SAFEbody Technology enables further broadening of the therapeutic index x ADG126 targets a unique epitope with broad species cross - reactivity x Dosed up to 200 mg/kg in GLP tox study, potent single and combination therapies for syngeneic tumor models x ~16
Slide 14: Building a Deep, Broad and Differentiated Pipeline
Building a Deep, Broad and Differentiated Pipeline, with 5 Candidates in IND - Enabling Studies and >50 in Discovery 14 - >50 programs across stages of discovery - 5 POWERbody and SAFEbody programs in IND - enabling studies, including two presented at ASH 2021 - All 5 IND - enabling programs have a
Slide 15: ADG152: Anti-CD20xCD3 Bispecific T-cell Engager from POWERbody Platform
ADG152: Anti - CD20xCD3 is First Bispecific T - cell engager from POWERbody Ρ Platform 15 - I ntegrates SAFEbody precision masking technology to minimize cytokine release syndrome (CRS) and on - target/off - tumor toxicities for an increased therapeutic index (~10 - fold higher) - Enhanced binding t
Slide 16: ADG153: A Highly Differentiated IgG1 Anti-CD47 SAFEbody
ADG153: A Highly Differentiated IgG1 Anti - CD47 SAFEbody ® 16 - Anti - CD47 antibody with IgG1 - mediated strong effector functions for potent tumor killing, while minimizing antigen sink and red blood cell (RBC) depletion - Integrates safety and efficacy into one single modality x Potency : M axim
Slide 17: Global Partnerships and Collaborations Validate Our Platform
Global Partnerships and Collaborations Validate Our Platform 17 SAFEbody ADC Development DPL Discovery Clinical Collaborations Validation by Other Entities − Three Ph 1b/2 trials with pembrolizumab − Ph 1b/2 trial of ADG106 and nivolumab in advanced NSCLC in Singapore − Licensing fee, up to $166M mi
Slide 18: Financial Summary
Financial Summary 18 As of June 30, 2021 As of December 31, 2021 Cash and cash equivalents (unaudited) US$208 million Approximately US$174 million
Slide 19: Thank you
ADAGENE Thank you 19 | ADAGENE